Cobas c 311 analyzer

Participants underwent a medical examination that included measurement of systolic blood pressure (SBP) and diastolic blood pressure (DBP), and obtaining a fasting blood sampling [50 (link)]. We retrieved, processed, and measured more cardiometabolic risk markers from fasting blood samples of participants who fulfilled the inclusion in the trajectory analysis. Serum cholesterol (total, LDL-C and HDL-C) were measured at the Paediatric Clinic Dortmund with the Advia 1650-Chemistry System analyser (Siemens Healthcare Diagnostics, Eschborn, Germany). We measured fasting plasma glucose (FPG) on a Roche/Hitachi Cobas c 311 analyzer (Basel, Switzerland). Triglycerides and high-sensitivity C-reactive protein (CRP) with the Roche/Hitachi Cobas c311 analyser (Roche diagnostics, Mannheim, Germany), interleukin (IL)-6 with the Human IL-6 Quantikine HS ELISA (R&D Systems, Wiesbaden, Germany), IL-18 with the Human IL‐18 ELISA (Medical and Biological Laboratories, Nagoya, Japan), adiponectin with the Human Total Adiponectin/Acrp30 Quantikine ELISA kit (R&D Systems), chemerin with the Human Chemerin ELISA (BioVendor, Brno, Czech Republic), and leptin with leptin Quantikine ELISA (R&D System) as described [51 (link), 52 (link)]. We considered SBP, DBP, triglyceride, HDL-c, FPG, CRP, IL‐6, IL‐18, adiponectin, chemerin, and leptin for the current study.

Hematological parameters were determined by using automated biochemistry analyzer (Roche/Hitachi cobas c 311 analyzer, Tokyo, Japan). GLB was calculated by subtracting ALB values from TP. The content of IgM, C3 and C4 and activity of LZM were determined by using commercial Fish ELISA kits and following manufacturer instructions (IgM: 17025, C3: 17181, C4: 17200, LZM: 17094, Quantikine^® ELISA kit, R and D Systems, Minnesota, MN, USA).

Plasma was stored at -80°C directly after blood collection and used for all assays which have been described in detail before [18 (link)]. Fasting plasma glucose levels were determined on a Roche/Hitachi Cobas c 311 analyzer (Basel, Switzerland). Plasma insulin was measured by ELISA (Mercodia, Uppsala, Sweden). As surrogate marker of insulin resistance, the homeostasis model assessment-insulin resistance (HOMA-IR) was calculated as fasting glucose (mmol/L) * fasting insulin (μU/ml) / 22.5.